In response to elevated SREBP1c, the expression of downstream targets acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS) was increased in both patients with NAFLD and animal models of the disease [97,98,99]. Here, SREBF1 is linked to metabolic dysfunction-associated steatotic liver disease.